This article was originally published in The Gray Sheet
A body of "poor quality" data suggests that head and neck cancer patients treated with radiation may experience a better quality of life following intensity-modulated radiotherapy compared to two-dimensional radiotherapy or three-dimensional conformal radiotherapy, the Agency for Healthcare Research and Quality said in a draft comparative effectiveness 1report released for comments July 24. That is the strongest statement possible based on what is largely insufficient evidence on the relative outcomes from four different head and neck cancer radiotherapy treatments, AHRQ says. Acknowledging that head and neck cancers are relatively rare, AHRQ urges more multicenter, randomized trials or at least observational studies with more prospective data. Comments are due Aug. 22
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.